Literature DB >> 3496118

Treatment of a low immunogenic experimental tumour with alloactivated or tumour-immune lymphocytes.

G Parmiani, L Grazioli, M Sensi, M P Colombo, M Rodolfo.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3496118     DOI： 10.1016/0304-419x(87)90004-7

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN： 0006-3002


× No keyword cloud information.
  2 in total

Review 1.  Susceptibility of human and murine drug-resistant tumor cells to the lytic activity of rIL2-activated lymphocytes (LAK).

Authors:  C Gambacorti-Passerini; L Rivoltini; M Radrizzani; R Supino; M Mariani; G Parmiani
Journal:  Cancer Metastasis Rev       Date:  1988-12       Impact factor: 9.264

2.  Therapeutic use of a long-term cytotoxic T cell line recognizing a common tumour-associated antigen: the pattern of in vitro reactivity predicts the in vivo effect on different tumours.

Authors:  M Rodolfo; C Bassi; C Salvi; G Parmiani
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.